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Abstract
Background: The etiologic agent of Chagas Disease is Trypanosoma cruzi. Acute infection results in patent parasitemia and
polyclonal lymphocyte activation. Polyclonal B cell activation associated with hypergammaglobulinemia and delayed
specific humoral immunity has been reported during T. cruzi infection in experimental mouse models. Based on preliminary
data from our laboratory we hypothesized that variances in susceptibility to T. cruzi infections in murine strains is related to
differences in the ability to mount parasite-specific humoral responses rather than polyclonal B cell activation during acute
infection.
Methodology/Principal Findings: Relatively susceptible Balb/c and resistant C57Bl/6 mice were inoculated with doses of
parasite that led to similar timing and magnitude of initial parasitemia. Longitudinal analysis of parasite-specific and total
circulating antibody levels during acute infection demonstrated that C57Bl/6 mice developed parasite-specific antibody
responses by 2 weeks post-infection with little evidence of polyclonal B cell activation. The humoral response in C57Bl/6
mice was associated with differential activation of B cells and expansion of splenic CD21highCD23low Marginal Zone (MZ) like
B cells that coincided with parasite-specific antibody secreting cell (ASC) development in the spleen. In contrast, susceptible
Balb/c mice demonstrated early activation of B cells and early expansion of MZ B cells that preceded high levels of ASC
without apparent parasite-specific ASC formation. Cytokine analysis demonstrated that the specific humoral response in the
resistant C57Bl/6 mice was associated with early T-cell helper type 1 (Th1) cytokine response, whereas polyclonal B cell
activation in the susceptible Balb/c mice was associated with sustained Th2 responses and delayed Th1 cytokine
production. The effect of Th cell bias was further demonstrated by differential total and parasite-specific antibody isotype
responses in susceptible versus resistant mice. T cell activation and expansion were associated with parasite-specific
humoral responses in the resistant C57Bl/6 mice.
Conclusions/Significance: The results of this study indicate that resistant C57Bl/6 mice had improved parasite-specific
humoral responses that were associated with decreased polyclonal B cell activation. In general, Th2 cytokine responses are
associated with improved antibody response. But in the context of parasite infection, this study shows that Th2 cytokine
responses were associated with amplified polyclonal B cell activation and diminished specific humoral immunity. These
results demonstrate that polyclonal B cell activation during acute experimental Chagas disease is not a generalized response
and suggest that the nature of humoral immunity during T. cruzi infection contributes to host susceptibility.
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Introduction
The protozoan parasite, Trypanosoma cruzi is the etiologic agent of
Chagas’ disease. Chagas disease is a chronic and debilitating
syndrome that affects millions of people in Latin America. Infection
with T. cruzi leads to patent parasitemia and systemic spread of the
parasite throughout the host during acute phase disease. Immune
control resolves patent parasitemia, but tissue infection persists for
the life of the host and leads to chronic phase disease in as many as
30 percent of infected individuals [1]. Due to the difficulties of
human studies, the majority of research regarding immune control
of parasite infection has been done in experimental murine models,
which develop detectable parasitemia during acute infection
followed by chronic tissue parasitism that mimics human disease.
Control of T. cruzi infection depends on clearance of blood
stream parasite through both innate and acquired immune
mechanisms. Macrophages, NK cells, T and B lymphocytes, and
the production of cytokines, which play key roles in regulating
both parasite replication and immune response [2], are required to
control parasitemia. The depletion or absence of any given innate
or adaptive effector mechanism leads to increased parasitemia and
susceptibility to disease [3,4,5,6,7,8,9].
Humoral immunity is important for control of parasite infection
as B cell depletion leads to increased parasitemia and mice
www.plosntds.org 1 July 2010 | Volume 4 | Issue 7 | e733
succumb to otherwise non-lethal infection [7]. Adoptive transfer of
antibodies from late stage T. cruzi infected mice to naı¨ve mice leads
to rapid clearance of parasite from circulation [10]. Transfers of
splenocytes from mice that have recovered from acute phase
infection to naı¨ve mice confers protection against lethal T. cruzi
infection, which is abolished by removal of B lymphocytes, but
relatively insensitive to T cell or macrophage depletion [11]. Yet,
evidence indicates that the majority of B cells are not parasite-
specific during early T. cruzi infection [12].
Polyclonal B cell activation that leads to hypergammaglobulin-
emia and delayed specific humoral immune response is generally
accepted as a characteristic of acute phase Chagas disease in
humans and is reported in rodent experimental models of T. cruzi
infection [13,14,15,16,17]. The acute phase polyclonal response to
T. cruzi infection is associated with delayed specific responses [14].
Different IgG isotypes have been implicated in polyclonal B cell
activation and parasite-specific antibody responses [18,19,20,21].
Several parasite encoded mitogenic proteins have been identified,
but the role of each has yet to be elucidated [22,23,24,25,26,27]. B
cell expansion in the spleen and lymph nodes during acute T. cruzi
infection is associated with polyclonal, rather than specific
responses [28,29]. Fas/FasL mediated apoptosis of parasite
specific B cells and immature B cells in the bone marrow (BM)
has also been reported in Balb/c mice [30,31,32]. Studies in Balb/
c XID mice show that the depletion of B cell subsets in this model
led to an increased resistance to disease that was associated with
improved IFN-c responses, decreased hypergammaglobulinemia,
and a skewed natural antibody repertoire [33,34,35]. Limited
studies of B cell dynamics during T. cruzi infection in resistant
versus susceptible mice have been reported [20,28].
Marginal zone (MZ) and follicular (FO) B cells constitute two
functionally and anatomically distinct B cell subsets within the
spleen [36,37,38,39,40]. MZ B cells are located at the marginal
sinus of the spleen, making these cells first line responders to
pathogens in the blood. MZ B cells are more responsive to TI-
antigens, respond quickly with natural antibody responses, and
generate short-term plasma cells [41]. MZ are also able to migrate
to the follicles and participate in germinal center T cell dependent
(TD) reactions [42]. FO B cells circulate through the lymph and
are found in B cell follicles of the spleen. FO B cells respond to TD
antigen and can become long-term plasma cells or memory B cells
[43]. Due to their differential location and function, these two B
cell subsets can have distinct roles in the development of specific
versus polyclonal B cell responses to pathogens [36,37,44,45].
While mouse models have been informative for analysis of
immune responses to T. cruzi infection, inbred mouse strains
experience variable disease progression and severity [46,47].
Disease progression in these models also differ depending upon
the strains of parasite used [48]. In general, Balb/c mice are more
susceptible to infection compared to C57Bl/6 mice in terms of
increased parasitemia and mortality given a similar parasite
challenge [49]. Kinetic analysis of cytokine production by
lymphocytes provides evidence that resistance in C57Bl/6 mice
is associated with increased early production of IFN-c [49].
Further studies show that immunization protocols capable of
inducing polarized Th1 but not Th2 responses are able to protect
Balb/c mice against T. cruzi challenge, but transfer of CD4 T cell
alone was not enough to confer protection to naı¨ve mice [50].
While these studies indicate that Th1 versus Th2 responses are
correlated with protection versus resistance, the complete profile of
effector mechanisms leading to increased resistance in Th1 skewed
mice has yet to be elucidated.
In the present study, we analyzed the humoral response to T.
cruzi experimental infection of susceptible Balb/c versus resistant
C57Bl/6 mice. We infected Balb/c and C57Bl/6 mice with
isolates from Y-strain parasite that generated similar timing and
magnitude of initial patent parasitemia. The kinetics, magnitude,
and isotype of the parasite-specific and total circulating antibody
responses during acute T. cruzi infection were examined. We
further evaluated humoral responses in the spleen and the
association of parasite-specific antibody secreting cells (ASC) with
activation of B cells and expansion of B cell subsets, as well as the
expansion and activation of splenic T cells. The combined results
of this study demonstrate that resistant C57Bl/6 mice generated
parasite-specific humoral responses that were associated with
decreased hypergammaglobulinemia, differential kinetics of splen-
ic B cell activation and B cell subset expansion, improved T cell
help, and early IFN-c production compared to more susceptible
Balb/c mice.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national animal welfare bodies
and all animal work was approved by the Institutional Animal
Care and Use Committee of the University of Pittsburgh
(Assurance Number A3187-01).
Parasites and Mice
Balb/c and C57/Bl/6 mice were obtained from Jackson
Laboratories and maintained in specific pathogen free housing.
Mice husbandry and procedure protocols were reviewed and
performed in accordance with the University of Pittsburgh IACUC.
Y-strain parasites were grown in NIH 3T3 fibroblast cells and
harvested by standard technique [51]. Briefly, 3T3 fibroblasts were
infected with trypomastigote parasites and cultured for 2 days at 37uC
(5% CO2) in DMEM (Gibco) supplemented with 10% FBS, 10 mM
HEPES, 0.2 mM sodium pyruvate, and 50 mg/mL gentamicin, to
allow infection of the growing cells. On day 3, the media was
exchanged and the culture was moved to a 34uC incubator and
Author Summary
Chagas disease, caused by the protozoan parasite
Trypanosoma cruzi, affects 10–12 million people in Latin
America. Patent parasitemia develops during acute dis-
ease. During this phase, polyclonal B cell activation has
been reported to generate high levels of serum antibody
with low parasite specificity, and delayed protective
humoral immunity, which is necessary to prevent the host
from succumbing to infection. In this manuscript, data
show that relatively resistant mice have improved parasite-
specific humoral immunity and decreased polyclonal B cell
activation compared to susceptible mice. Parasite-specific
humoral immunity was associated with differential expan-
sion of B cell subsets and T cells in the spleen, as well as
with increased Th1 and decreased Th2 cytokine produc-
tion. These data suggest that host susceptibility/genetic
biases impact the development of humoral responses to
infection. Th2 cytokines are generally associated with
improved antibody responses. In the context of T. cruzi
infection of susceptible mice, Th2 cytokines were associ-
ated with increased total antibody production concomi-
tant with delayed pathogen-specific humoral immunity.
This study highlights the need to consider the effect of
host biases when investigating humoral immunity to any
pathogen that has reported polyclonal B cell activation
during infection.
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maintained under anerobic conditions until harvest of the tissue
derived trypomastigotes (TCT) from the culture supernatant. To
establish models of infection for analysis of kinetics and magnitude of
parasite-specific humoral immunity versus polyclonal B cell
activation in resistant C57Bl/6 and susceptible Balb/c mice, we
evaluated experimental infection using two variants of T. cruzi Y-
strain (Y-US and Y-Br). The LD50 was established for each model,
using intraperitoneal injection of TCT in PBS plus 1% glucose.
Survival curves for these infections indicated that the Balb/c mice
were much more susceptible to the Y-Br variant, with an
approximately 1000 fold higher LD50, but succumbed to infection
with different kinetics than did C57Bl/6 mice (Figure S1A). At
similar LD50, parasitemia was delayed in Y-Br-infected Balb/c
compared to Y-Br-infected C57Bl/6 (Figure S1B). In contrast, using
the Y-US variant, Balb/c mice experienced initial peak parasitemia
comparable with C57Bl/6 mice given a similar LD50 dose of the Y-
Br variant (Fig 1A). In both mouse strains, a dose of parasite equal to
approximately 0.256LD50 was used to allow direct comparison of
humoral responses in a sub-lethal infection of relatively resistant
versus susceptible mice. The approximate 0.256LD50 dose
corresponded to 2.56105 Y-US in Balb/c mice and 6.256103 Y-
Br in C57Bl/6 mice. Control mice were inoculated with the same
dose of parasite after it had been heat-inactivated at 56uC for
25 minutes. Parasitemia was monitored by applying blood diluted
1/4 in RBC lysis buffer (150mM NH4Cl, 10mM NaHCO3, 115uM
EDTA) to a hemocytometer and counting at 4006. Blood was
collected at multiple time-points post infection for analysis by
ELISA.
rCRP Cloning
A full-length cDNA encoding the T. cruzi CRP was isolated by
reverse transcription-PCR as previously described [52]. The T.
cruzi CRP cDNA encoding the mature protein (starting at
nucleotide 303) was subcloned into the pTrcHis expression vector
(Invitrogen). E. coli strain SURE (Stratagene) were transformed
with pTrcHis-CRP DNA for recombinant protein production with
a histidine tag, as previously described [51]. For eukaryotic
expression, CRP was cloned into pcDNA3 with the glycosylpho-
sphatidylinositol (GPI) anchor signal sequence from human decay
accelerating factor (daf), [53].
Gene-Gun Immunization
pcDNA3_CRP DNA was purified from E. coli using endotoxin -
free Mega prep kits (Qiagen). The DNA was coated on 1.0 mm
gold particles (Bio-Rad) and loaded into Tefzel tubing (Bio-Rad)
[54]. DNA (8 mg) was administered by Helios Gene-gun (Bio-Rad)
at 400 psi, in two shots per mouse on shaved abdomen [55]. Four
inoculations were performed at monthly intervals. Immunized
mice were bled after boosting and the blood processed to obtain
sera.
Protein Purification
Expression of recombinant protein was induced by isopropyl-b-
D-thiogalactoside (IPTG) (IBI Scientific, Peosta, IA) in trans-
formed E. coli and the cells harvested by centrifugation (6,000
RCF, 10 min., 4uC). The resulting cleared lysate was prepared
under denaturing conditions and bound to cobalt metal affinity
resin according to the Talon instruction manual with slight
modifications (Clontech, Mountain View, CA). During binding of
lysate to resin, 5–10mM imidazole (Sigma) was added into the
binding buffer (50mM Tris, 300mM NaCl, pH 7.2). Protein was
bound to the resin in batch for 2 hours. The bound protein was
further washed and packed into a disposable column. Imidazole
(150mM) was used to elute bound protein. Protein concentration
in eluted fractions was determined by Bradford assay.
Quantitative IgM and IgG ELISA
4 HBX Immulon ELISA plates (Thermo Scientific) were coated
with 100ng of goat-anti-mouse Ig antibody (SouthernBiotech)
overnight at 4uC, washed, and blocked with 1% milk in T-PBS
(0.05% Tween-20, 16PBS), washed and stored at 220uC until
use. Serum samples were stored at less than 220uC then thawed
and maintained at 4uC during ELISA analysis. Serum was diluted
in milk-T-PBS and applied to coated plates. A standard curve was
generated with mouse IgM or IgG (SouthernBiotech). Goat anti-
mouse IgM or IgG conjugated with HRP was used as the
secondary antibody (SouthernBiotech). After incubation with
secondary antibody, plates were washed and developed with
OPTEIA (BD) and analyzed for color change (OD450). Standard
curve fit and calculation of unknowns was performed using Prism
software (GraphPad).
rCRP and Whole Parasite Specific ELISA
For rCRP analysis, 4 HBX Immulon ELISA plates (Thermo
Scientific) were coated with 100 ng of purified protein and
incubated overnight at 4uC. For whole parasite ELISA, plates
were coated with 26105 heat-inactivated TCT per well and
incubated overnight at 4uC. Plates were washed and blocked and
Figure 1. Disease severity and parasitemia in Balb/c and C57Bl/6
mice. Mice were injected with tissue culture trypomastigotes
(0.256LD50; i.p.). A, Parasitemia levels were analyzed in mouse blood at
6–9, 15, and 28 days post-infection (n$5 mice per group). B, Mouse
weights were collected at multiple time-points post-infection and the
change from baseline determined for each mouse (n=5 mice per group).
doi:10.1371/journal.pntd.0000733.g001
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stored at 220uC until used. Mouse serum was diluted in block and
applied to ELISA plates overnight at 4uC. Plates were washed and
developed with the appropriate secondary antibody. The estimat-
ed reciprocal endpoint titer (RET) was determined graphically
based on the OD450 values from equivalent dilution of pooled
mouse pre-immunization serum samples. RET was defined as the
first dilution with a value below the pre-immune OD450 plus SD
(two to three replicates). Alternatively, equivalent units, deter-
mined by dividing the OD450 of test serum by the OD450 of pre-
immune serum, were reported at a single dilution of sera.
Antibody Secreting Cell (ASC) ELISPOT
Spleens were processed for single cells, by gentle mashing in a
40mM cell strainer, treated with RBC lysis buffer (150mM NH4Cl,
10mM NaHCO3, 115uM EDTA), washed with 16PBS, and
suspended in cRPMI. Multiscreen HTS 96-well ELISPOT plates
(BD Biosciences) were coated with 2.5 mg/mL of rCRP or 5 mg/
mL of goat anti-mouse Ig (SouthernBiotech) and incubated
overnight. ELISPOT plates were washed with T-PBS and blocked
with cRPMI for 2 hrs. Blocking media was removed and cells were
plated into the ELISPOT plates (5 wells per sample) at several
dilutions. After 5–6 hrs, the cells were washed off with PBS (36)
followed by T-PBS (36). Secreted antibodies were detected by
incubating with anti-mouse IgG conjugated to biotin (16 hrs, 4uC),
washing with T-PBS (3–46), incubation with avidin-peroxidase
complex (30 min, RT)(Vector Laboratories, Burlingame, CA),
washing with T-PBS (36) and PBS (36), followed by incubation
with AEC ELISPOT substrate (8 min, RT)(BD Biosciences). The
reaction was stopped by washing with PBS. Spots were analyzed
using ImmunoSpot image acquisition 4.5 and ImmunoSpot 5.0
Professional DC software (ImmunoSpot). The frequency of ASC
per 106 splenocytes was determined [56,57,58].
Flow Cytometry
Splenocytes were isolated, counted, and plated at 56105 cells
per well in 96 well plates. Cells were collected by centrifugation
(5006g, 5 min, 4uC) and washed with FACS staining buffer
(16PBS with 2.5% FCS, 1% goat serum, and 1% human AB
serum). 107 cells per mL were incubated with fluorescently labeled
abs, diluted in FACS buffer, for 20 min on ice or 5 min at 4uC.
Abs used for staining included anti-CD19 (MB19-1), CD3 (17A2),
CD69 (H1.2F3), CD86 (GL1), CD21 (eBio4E3), CD23 (B3B4),
CD4 (RM4-5, L3T4), CD8a (53-6.7), PanNK (DX5), CD95
(15A7), CD95L (MFL3). For determining population gating on
cells with multiple stains, florescence minus one controls were
used. For analysis of surface activation, B and T cells were counter
stained and doublets were excluded to ensure only the reported
lymphocyte population was analyzed. Antibodies were purchased
from BD Biosciences or eBioscience. Data were collected on an
LSRII (BD Biosciences) and analyzed using FlowJo software (Tree
Star). The data were analyzed using bi-exponential transformation
for complete data visualization.
Statistical Analysis
2-way ANOVA was used for comparing the two mouse models
over time. Bonferroni post-test analysis, Student’s t test, or Mann-
Whitney tests were used for comparison of individual doses or time-
points, either between infected and control mice or between models.
Results
Balb/c and C57Bl/6 Models of T. cruzi Infection
Balb/c and C57BL/6 mice were infected with a sub-lethal
parasite dose (0.25 LD50) of TCT. The magnitude and timing of
the initial peak parasitemia was similar in both models, although
Balb/c mice experienced a second wave of parasitemia at day 15
post-infection that was not evident in the C57Bl/6 mice (Fig 1A).
Furthermore, Balb/c mice displayed significant weight loss by day
15 post-infection (p = 0.005, Student’s t-test) that did not rebound
until after acute infection (.30 days post-infection), whereas
C57Bl/6 mice maintained their weight over the course of infection
(p = 0.009, 2-way ANOVA) (Fig 1B). These data show that given
the same relative dose with similar early parasitemia kinetics,
Balb/c mice remained more susceptible to the adverse effects of T.
cruzi infection than were C57Bl/6 mice.
Resistant Mice Have Decreased
Hypergammaglobulinemia and Improved Parasite
Specific Antibody Response
To investigate systemic antibody responses during infection,
serial pooled serum samples were collected and analyzed for levels
of circulating IgG and IgM as well as antibodies specific to a T.
cruzi surface antigen, T. cruzi complement regulatory protein
(CRP), a member of the transialidase superfamily [51,59,60,61].
The profiles of total IgM and IgG response in Balb/c and C57Bl/
6 mice were significantly different during early infection (Fig 2A).
C57Bl/6 mice had more circulating IgM after infection than did
Balb/c mice. In contrast, Balb/c mice had significantly greater
hypergammaglobulinemia post-infection than did C57Bl/6 mice
(Fig 2B).
Parasite-specific antibody responses were evaluated by measure-
ment of T. cruzi CRP-specific IgM and IgG following infection of
Balb/c and C57Bl/6 mice. C57Bl/6 mice developed CRP-specific
antibodies by day 20 post-infection (3.360.5 fold increase from
baseline) (Fig 2B), whereas Balb/c mice had minimal CRP-specific
responses until late in acute phase (Fig 2B). Delayed parasite-specific
IgG response was also evident when Balb/c mice were inoculated
with the low doses of the Y-BR variant (data not shown). In contrast,
to the relative delay in CRP specific antibody responses in Balb/c
versus C57Bl/6 mice during experimental infection, genetic
immunization with CRP resulted in an improved CRP-specific
IgG response in Balb/c mice compared to C57Bl/6 mice (Fig 2C).
Taken together, these data suggest that the delayed CRP-specific
antibody response in Balb/c mice compared to C57Bl/6 mice was
not due to an inherent inability of Balb/c mice to respond to CRP
antigen, but rather a host-pathogen interaction leading to
diminished generation of parasite-specific antibody responses.
A Th1 Skewed Early IFN-c Response in Resistant Mice
versus Delayed IFN-c and Increased Th2 Cytokines in
Susceptible Mice
Cytokines influence the generation of cellular and humoral
responses to infection and can be differentially produced in resistant
versus susceptible mice during T. cruzi infection [49,50]. Cytokine
production from T helper (Th) cells fall broadly into classification as
T helper type 1 (Th1), T helper type 2 (Th2), or T helper 17 (Th17)
categories: Th1 are defined by production of pro-inflammatory
cytokines, particularly IFN-c and TNF, Th2 by IL-4, IL-5, and IL-
10, and Th17 cells by IL-17 [62]. To evaluate levels of circulating
cytokines post-infection, multi-plex cytokine analysis was performed
on serum samples from day 8, 15, and 28 post-inoculation, and
compared to control mice inoculated with heat-inactivated parasites.
The timing of IFN-c, TNF-a IL-10, IL-5, and IL-6 responses were
significantly different in Balb/c mice compared to C57Bl/6 (Fig 3).
In C57Bl/6 mice, an early significant IFN-c response was evident
along with increased IL-6 and IL-10, which then decreased to near
control levels by day 15 post-infection. In comparison to C57Bl/6
Host Resistance and Humoral Immunity to T. cruzi
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mice, Balb/c had delayed IFN-c and IL-6 response, an early IL-10
that persisted to day 15 and increased by day 28 post-infection, and
IL-5 levels that were significantly elevated by day 15 and remained
so at day 28 post-infection. TNF-a levels increased earlier in C57Bl/
6 mice than in Balb/c mice. In addition, Balb/c mice had IL-4 by
day 28 post-infection, whereas Balb/c controls and C57Bl/6 mice
(infected and control) did not produce detectable IL-4 in their serum
(data not shown). These data indicate that C57Bl/6 responded to
infection with an early Th1 biased cytokine response, whereas Balb/
c mice responded to infection with a more Th2 skewed response.
IgG1 and IgG2a Predominate in Total and Specific
Response of Susceptible Mice versus a More Mixed
Isotype Response in Resistant Mice
Different IgG isotypes have been implicated in effective
immunity and polyclonal B cell responses to T. cruzi
[18,19,20,21]. To compare the level of IgG isotype switching in
Balb/c versus C57Bl/6 mice, serum samples were analyzed over
the course of infection for concentration of IgG1, IgG2a (Balb/c)
or IgG2c (C57Bl/6), IgG2b, and IgG3 [63]. The serum levels for
each isotype were significantly different in Balb/c versus C57Bl/6
mice over the time-points tested (day 8 through 125, post-
infection) (Fig 4A). IgG1 and IgG2a were increased in Balb/c mice
compared to C57Bl/6 mice (p,0.0001 for each, 2-way ANOVA).
IgG2b was increased in C57Bl/6 mice compared to Balb/c mice
(p,0.0001, 2-way ANOVA). The profile of IgG3 showed an
overall difference that was significant at days 15 and 125 post-
infection (p,0.01 and p,0.001, respectively, by Bonferroni post-
test; p = 0.0007 by 2-way ANOVA). Serum samples from infected
mice were analyzed for CRP-specific IgG isotype responses at day
28 post-infection, revealing a significant difference in the isotype
profile of parasite specific IgG (p = 0.0006, 2-way ANOVA), with
predominantly IgG1 and IgG2a produced in Balb/c, with a mixed
response including IgG2b and IgG3 in C57Bl/6 mice (Fig 4B).
Resistant Mice Generated Parasite Specific IgG ASC;
Susceptible Mice Generated Non-Specific IgG ASC and
Have Increased Numbers of B Cell Blasts
Acute T. cruzi infection has been reported to induce expansion
of B and T cell subsets in the spleen without generation of parasite
Figure 2. Circulating Total and CRP-specific IgM and IgG after T. cruzi infection. A, Infected mice (n = 5 per group) were bled at multiple
time-points post-infection and their pooled sera analyzed for total IgM (top) and total IgG (bottom), with triplicate repeats for each time-point. B,
Pooled sera were analyzed for CRP-specific IgM and CRP-specific IgG by ELISA in duplicate. C, Balb/c generate a higher titer CRP-specific IgG than do
C57Bl/6 mice in response to genetic immunization (p = 0.002). Each data point represents one mouse, data pooled from several individual
experiments. Balb/c are represented by open squares, solid line; C57Bl/6 mice by closed circles, dashed line. * p,0.05, *** p,0.001 by Student’s t test
comparing Balb/c and C57Bl/6 models.
doi:10.1371/journal.pntd.0000733.g002
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specific responses [28,64]. To determine whether resistant and
susceptible mice display altered humoral responses in the spleen,
splenocytes were analyzed for total B cells and large B cell blasts,
as well as total and parasite-specific IgG antibody secreting cells
(ASC) after T. cruzi infection (Fig 5). T. cruzi infection led to
expansion of splenic B cells in both Balb/c and C57Bl/6 mice
compared to controls by day 8 post infection (1.9260.60 fold
increase p,0.01 and 1.5760.54 fold increase p = 0.04, respec-
tively). (Fig 5A). B cell blasts, defined by their increased size and
granularity, were increased to a greater extent in Balb/c mice
compared to C57Bl/6 mice post-infection (Fig 5B). Balb/c mice
had B cell blasts levels $2.4 fold higher than controls at day 8 and
15 post infection (p = 0.002 for both time-points), with levels falling
to 1.760.9 by day 28 post-infection (p = 0.03). In contrast, C57Bl/
6 mice first experienced a significant increase in total B cell blasts
compared to controls (2.060.9, p = 0.02) at day 15 post-infection.
Elevated levels of total IgG ASC were seen in both models but to a
greater extent in Balb/c mice (Fig 5C). Furthermore, the increase
in IgG ASC in Balb/c mice was not associated with an increase in
parasite-specific ASC measured by CRP-specific ASC (Fig 5D). In
contrast, C57Bl/6 show a parasite-specific response in the spleen
at day 15 post-infection (Fig 5D). These data indicate that splenic
B cells in Balb/c mice were more susceptible to T. cruzi induced
polyclonal activation, but were less capable of generating a specific
response to T. cruzi antigen. C57BL/6 mice were able to generate
specific IgG ASC against a parasite specific protein, indicating an
improved humoral response in the spleens of these mice.
Furthermore, these data demonstrate that while there were similar
changes in total B cell numbers in these two mouse models during
T. cruzi infection, these changes were associated with different
outcomes and that these differences in B cell effector function were
also linked to phenotypic differences, such as blast formation.
Analysis of B Cell Activation by Surface Expression of
CD69, CD86 Fas, and FasL
To analyze activation status of splenic B cells post-infection,
flow cytometry was performed to measure surface expression of
CD69, CD86, CD95 (Fas) and CD95L (FasL) at days 8, 15, and
28 post-inoculation, comparing expression on B cells in infected
mice to control mice receiving heat-inactivated parasite (Fig 6).
CD69 was increased post-infection in both models, but with
different profiles (p = 0.0002, 2-way ANOVA). C57Bl/6 mice
initially had higher CD69 on the surface of B cells (4.662.2 fold
higher than controls at day 8 p = 0.002), which then decreased
Figure 3. Cytokine profile after T. cruzi infection. Luminex analysis of cytokine levels in mouse serum samples at days 8, 15, and 28 post-
infection. Values are reported as the concentration in infected mice relative to control mice receiving heat-inactivate parasite. Balb/c are represented
by open squares, solid line; C57Bl/6 mice by closed circles, dashed line. * p,0.05, ** p,0.01, *** p,0.001 by Bonferroni post-test after 2-Way ANOVA
comparing Balb/c and C57Bl/6 models (p values reported on graphs) and/or Student’s t test.
doi:10.1371/journal.pntd.0000733.g003
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over the course of infection. Balb/c mice maintained approxi-
mately a 2 fold elevation in CD69 expression (2.360.2 fold higher
than controls at day 8 p,0.0001). CD86 was increased post-
infection in both models, but with different profiles (p = 0.0001, 2-
way ANOVA). CD86 was initially elevated on B cells in both
strains, then decreased in C57Bl/6 mice and increased in Balb/c
mice at d28 post-infection. In both models, Fas and FasL positive
B cells were increased post-infection, but with different profiles
(p,0.0001 and P = 0.03, respectively, 2-way ANOVA). Fas and
FasL on B cells in infected C57Bl/6 mice increased between d8
and d15, then declined between d15 and d28. In contrast, Fas and
FasL on B cells in infected Balb/c mice increased between d15 and
d28 post-infection. Together, these data indicate that B cells were
differentially activated in susceptible versus resistant mice.
Differential B Cell Subset Profiles in Resistant versus
Susceptible Mice
FO and MZ B cells are functionally and phenotypically distinct
B cell populations within the spleen occupying distinct locations in
the spleen. MZ B cells are poised at the marginal sinus of the
spleen, and these cells are a source of natural antibody and T-
independent (TI) responses [65,66]. In contrast, FO B cells are
located in spleen follicles and respond to antigen in a T cell
dependent (TD) manner [39]. To analyze changes in B cell subsets
as defined by phenotype, B cell gates were determined based on
controls and naı¨ve mice, using published population statistics as a
guide [39]. B cell subset populations were defined as
CD19+CD21highCD23low/2 (MZ B cells), CD19+CD21intCD23+
(FO B cells) and CD19+CD21lowCD23low/2 cells (transitional/
newly formed B cells, or cells that may have lost CD21 and CD23
expression due to activation). This gating strategy has been used to
demonstrate changes in phenotypically defined MZ and FO B cell
splenic subsets due to infection with other microbes
[36,37,67,68,69]. While CD21 and CD23 levels have been shown
to be modulated by virus [70], in particular in B cells infected with
virus [71], the extent that other microbes modulate expression of
these markers has not been determined. Analysis of CD21 and
CD23 levels on B cells from T. cruzi infected mice indicates that
the expression of both markers decreased overall on B cells by day
8 post-infection in resistant C57Bl/6 mice, after which expression
increased over the course of infection; CD21 remained relatively
unchanged in susceptible Balb/c mice at day 8 and 15, then
slightly increased at day 28 post-infection, while CD23 levels were
decreased at every time-point analyzed (Fig 7A). The changes in
expression of these markers on total B cells were then reflected in
apparent changes in these phenotypically defined B cell subsets
post-infection with T. cruzi in both mouse models. Representative
plots of B cell subsets for C57Bl/6 and Balb/c mice at d8 post-
infection are shown in Figure 7B.
In Balb/c mice, the percentage of CD19+CD21intCD23+
(phenotypically defined as FO B cells) within the B cell gate
decreased to 36617 percent of controls (p,0.0001) and in C57Bl/
6 decreased to 74641 percent of controls (p = 0.02), which was a
significant retention of FO B cells in C57Bl/6 mice compared to
Balb/c mice (Fig 7C), although absolute numbers of FO B cells
were not significantly different from controls in either model.
Analysis of FO B cells within the total B cell blast population
indicates that FO B cell blasts represent a higher proportion of the
total B cell blasts at day 8 and 15 post-infection in resistant C57Bl/
6 mice than in susceptible Balb/c mice (p,0.01 for both time-
points) (Fig 7C).
CD19+CD21highCD23low/2 splenic B cells (defined as MZ by
phenotype) responses also differed in Balb/c mice and C57Bl/6
mice. The percentage of B cells with the MZ phenotype was
significantly different in Balb/c versus C57Bl/6 mice (p,0.0001,
2-way ANOVA). While in Balb/c mice, MZ B cells accounted for
an increased percentage of the total B cells at d8, in C57Bl/6 mice,
the percentage of MZ B cells were decreased (Fig 7C). The
percentage of B cells accounted for by MZ remained elevated at all
three time-points for Balb/c mice. C57Bl/6 experienced an
increased percentage of MZ B cells at d15 post-infection, which
then declined by d28 post-infection. Absolute numbers of MZ B
cells were significantly different in Balb/c versus C57Bl/6 mice
over the course of infection (p,0.0001) (Fig 7C). By d8 post-
Figure 4. Antibody isotype and cytokine profile after T. cruzi
infection. A, Serum samples from infected mice were analyzed by
ELISA to determine the isotype of the total Ig at days 8, 15, 28, and 125
post-infection. For each isotype the profile was significantly different in
Balb/c versus C57Bl/6 mice. IgG1 and IgG2a were increased in Balb/c
mice compared to levels of IgG1 and IgG2a in C57Bl/6 mice,
respectively (p,0.0001, 2-way ANOVA). IgG2b was increased in C57Bl/
6 mice compared to Balb/c mice (p,0.0001, 2-way ANOVA). The profile
of IgG3 showed an overall difference that was significant at days 15 and
125 post-infection (p,0.01 and p,0.001, respectively, by Bonferroni
post-test; p = 0.0007 by 2-way ANOVA). Five mice were used per group
per time-point. B, Serum samples from infected mice were analyzed for
CRP-specific IgG isotype responses at day 28 post-infection by
determining reciprocal endpoint titers (RET) using pre-infection sera.
p = 0.006 by 2-way ANOVA comparing the CRP-specific isotype profile
of Balb/c versus C57Bl/6 mice. Five mice were used per group.
doi:10.1371/journal.pntd.0000733.g004
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Figure 5. Splenic B cell expansion with or without parasite specific ASC. A, Splenocytes were stained and analyzed by flow cytometry for
enumeration of B cells. B, B cells were analyzed by forward and side scatter for blast formation. These plots show the total splenic B cells in infected
mice compared to the total number of splenic B cells in control mice of the same genotype. C, B cell ELISPOT analysis was completed to enumerate
total IgG ASC from spleens of infected and control mice (n = 5 mice per group per time-point). The results are presented as the ratio of infected to
average control of the same genotype. D, B cell ELISPOT analysis was used to enumerate the frequency of CRP-specific IgG ASC in the spleen of
infected mice (n = 5 mice per group per time-point). Balb/c are represented by open squares, solid line; C57Bl/6 mice by closed circles, dashed line.
** p,0.01, *** p,0.001 by Bonferroni post-test after 2-Way ANOVA comparing Balb/c and C57Bl/6 models (p values reported on graphs).
doi:10.1371/journal.pntd.0000733.g005
Figure 6. Expression of CD69, CD86, Fas, and FasL on splenic B cells. Splenocytes were harvested and stained for analysis by flow cytometry
at multiple time-points post-infection with T. cruzi in Balb/c and C57BL/6 mice. Balb/c are represented by open squares, solid line; C57Bl/6 mice by
closed circles, dashed line. ** p,0.01, *** p,0.001 by Bonferroni post-test after 2-Way ANOVA comparing Balb/c and C57Bl/6 models (p values
reported on graphs) and/or Student’s t test.
doi:10.1371/journal.pntd.0000733.g006
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infection, MZ B cell numbers were increased 4.562.3 fold above
controls in Balb/c mice (p = 0.01). In contrast, MZ B cell numbers
were similar to controls in C57Bl/6 mice (0.8360.29, p = 0.4). MZ
B cell numbers were increased at d15 post-infection in C57Bl/6
and then declined, but remained elevated above controls at d28
post-infection. Analysis of CD19+CD21highCD23low/2IgMhigh B
cells showed these same trends of altered B cell numbers (data not
shown). The percent of total B cell blasts that were represented by
the MZ phenotype followed this same pattern of increased
representation in the B cells from susceptible Balb/c mice,
significantly more than in the resistant C57Bl/6 mice (p,0.0001).
CD19+CD21low/2CD23low/2 B cells numbers and percentages
within the B cell gate were expanded in both models by day 8,
Balb/c mice experienced further increased numbers and levels
measured at d15 post-infection, whereas C57Bl/6 mice did not
(p,0.0001, p = 0.002, numbers and percentage of B cells,
respectively)(Fig 7C). These cells represented similar amounts of
the total B cell blasts for both models until day 28 post-infection,
when the numbers of blast cells represented by this subset
decreased in Balb/c mice compared to C57Bl/6 (p,0.001).
Splenic T Cells Expand and Were Activated in Resistant
Mice
To determine the expansion and activation of splenic T cells,
the number of total T cells and T cell blasts were assessed at days
8, 15, and 28 post-inoculation, comparing T cells in infected mice
to control mice receiving heat-inactivated parasite (Fig 8A,B).
C57Bl/6 mice had increased T cells at d15 that decreased but
remained elevated by d28 (Fig 8A). This coincided with higher
levels of T cell blasts at d15 (Fig 8B). Balb/c mice did not have
increased T cells, although T cell blasts were increased at d15.
CD69 expression on T cells was significantly increased compared
to controls in both models and to a similar extend at day 8 post-
infection (3.660.3 for Balb/c and 2.961.3 for C57Bl/6, p,0.01
compared to control, p = 0.12 between models). CD69 expression
diverged at day 28 post-infection, when C57Bl/6 T cells had
CD69 levels comparable to controls and Balb/c T cells had
3.260.8 fold increased CD69 expression compared to controls
(p = 0.0002) and compared to the previous time point (1.962.6
p = 0.004). Fas and FasL profiles were significantly different on T
cells from Balb/c versus C57Bl/6 mice (Fig 8C), especially at d15.
CD4 and NKT cells levels were significantly higher in C57Bl/6
mice compared to Balb/c mice at d15 post-infection (Fig 8D).
C57Bl/6 mice maintained or slightly increased splenic CD4
numbers at d15 pi, whereas Balb/c mice had decreased CD4
numbers post-infection (Fig 8D).
The results presented in this study demonstrate that increased
polyclonal B cell antibody responses were associated with
decreased parasite-specific humoral immunity and increased
disease susceptibility during T. cruzi infection (Figure 9). Hyper-
gammaglobulinemia was more pronounced in susceptible Balb/c
mice and was associated with delayed generation of parasite-
specific antibodies. The parasite-specific humoral immunity in the
resistant C57Bl/6 mice was concomitant with a Th1-skewed
cytokine burst. In comparison, delayed and then maintained Th2-
skewed cytokine production in Balb/c mice was associated with
polyclonal B cell activation. B cell activation in resistant mice was
associated with low levels of total ASC and appreciable parasite-
specific ASC in the spleen. Total B cell expansion and activation in
the spleen of susceptible mice was associated with the development
of high levels of antibody secreting cells (ASC) without detection of
parasite-specific response. Figure 9 provides a model for the
association of polyclonal versus parasite-specific antibody with
disease severity and cytokine responses in resistant and susceptible
mice. Furthermore, analysis of B cell surface markers (CD69,
CD86, Fas, FasL, CD21, CD23) indicated differential profiles in
the context of polyclonal versus parasite-specific activation in
resistant C57Bl/6 versus susceptible Balb/c mice. B cells with the
marginal zone (MZ) phenotype were differentially expanded in the
spleen of resistant C57Bl/6 mice in association with parasite-
specific responses. MZ-like B cells were expanded early and
remained elevated in susceptible Balb/c mice. Changes in T cell
surface marker expression (Fas, FasL, CD69) and subsets (CD4,
CD8, NK) were observed in resistant versus susceptible mice and
associated with differential humoral responses.
Discussion
As in many experimental models of infection, there are
significant differences in susceptibility to pathogens among mouse
strains; however the host-pathogen interactions that account for
these differences are not completely clear. In the case of T cruzi
experimental infection, protective cytotoxic CD8 responses and
Th1 responses have been well characterized [72,73,74,75]. The
extent of B cell activation during T. cruzi infection and its
association with effective parasite-specific immunity versus adverse
polyclonal responses remains unclear.
It has been previously been shown that T. cruzi induces
polyclonal B cell activation during acute infection and that B cell
mitogens are expressed by infectious trypomastigotes
[22,28,76,77]. It has been postulated that this aberrant B cell
response may contribute to a delayed parasite-specific humoral
response, thus promoting infection [12,14,33,76]. In this study, we
examined the humoral responses of two murine strains with
differing susceptibility to T. cruzi infection to 1) determine whether
induction of polyclonal B cell activation was associated with
increased disease susceptibility and 2) determine whether changes
in circulating cytokines, splenic B cell function and phenotype, and
splenic T cell activation and subset expansion were associated with
polyclonal versus parasite-specific humoral responses.
Analysis of total circulating IgG and IgM indicated that resistant
C57Bl/6 mice demonstrated increased total IgM followed by an
IgM response to a parasite specific antigen (CRP) (Fig 2). The IgM
responses in C57Bl/6 mice developed as parasites were cleared
from circulation and were followed by a rise in total IgG and then
parasite-specific IgG. In contrast, Balb/c mice had very little
change in total IgM in the blood post-infection and minimal
parasite-specific IgM responses. In contrast to the lack of IgM
Figure 7. Splenic B cell subset changes. Splenoctyes were harvested from infected and control mice at days 8, 15, or 28 post infection and
analyzed by surface markers for B cell populations. A, Analysis of CD21 and CD23 expression levels over the course of infection. B, Representative
contour plots from day 8 post-infection show gates used for subset determination. C, These plots show the relative change in splenic B cell
phenotype between infected and control mice. The first row graphs show percent of B cells accounted for by each of the subsets, the second row
graphs show the absolute numbers for each population, the third row graphs shows the percent of B cell blasts accounted for by each of the subsets.
In these sets of graphs, the y-axis shows the ratio of infected to average control (n = 5 mice per group per time-point). Graphs for a given population
are underneath that title. Balb/c are represented by open squares, solid line; C57Bl/6 mice by closed circles, dashed line. Reported p values indicate
the result of 2-way ANOVA analysis between Balb/c and C57Bl/6 mice. * p,0.05, ** p,0.01, *** p,0.001 by Bonferroni post-test after 2-Way ANOVA
comparing Balb/c and C57Bl/6 models (p values reported on graphs) and/or Student’s t test.
doi:10.1371/journal.pntd.0000733.g007
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response, Balb/c mice had an increased hypergammaglobulinemia
response compared to C57Bl/6 mice. The increased hypergam-
maglobulinemia evident in Balb/c mice was associated with a
further delay and diminished parasite-specific IgG response
compared to C57Bl/6. This lack of a robust IgG response to a
parasite specific antigen (CRP) in Balb/c mice during experimen-
tal infection with T. cruzi was not due to an inherent inability to
generate a response to this T. cruzi antigen, as evident by the
magnitude of the IgG response to CRP after genetic immunization
in Balb/c versus C57Bl/6 mice. Rather, these data suggest
underlying host-parasite interactions that determine the balance of
hypergammaglobulinemia versus the development of parasite
specific responses.
As Th responses play a role in the generation of specific immune
responses, as well as polyclonal B cell activation [21], we
hypothesized that the differential humoral immune response to
Figure 8. T cell expansion and activation in the spleen. Splenoctyes were harvested from Infected and control mice at days 8, 15, or 28 post-
infection and analyzed by surface markers for T cell populations. Populations are reported as the ratio of absolute cell numbers or geometric mean
florescent intensity (GeoMFI) on T cells in infected mice to the average absolute numbers for control mice. Data represent four-five infected mice per
time-point. Balb/c are represented by open squares, solid line; C57Bl/6 mice by closed circles, dashed line. * p,0.05, ** p,0.01, *** p,0.001 by
Bonferroni post-test after 2-Way ANOVA comparing Balb/c and C57Bl/6 models (p values reported on graphs) and/or Student’s t test.
doi:10.1371/journal.pntd.0000733.g008
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T. cruzi infection may be associated with differential production of
cytokines in these two models. Analysis of circulating cytokines
post-infection confirmed the skewing of Balb/c mice toward Th2
responses and the C57BL/6 mice toward Th1 responses (Fig 3).
These data are in agreement with previous reports that early Th1
IFN-c responses are associated with resistance to infection [50,78]
and that Th2 cytokines, especially IL-4 and IL-10 are associated
with susceptibility to infection [34,79,80,81,82,83,84]. The results
of the present study show that early Th1-skewed cytokine burst
was coincident with control of parasitemia and preceded the
generation of parasite-specific humoral immunity in resistant
C57Bl/6 mice (Fig. 9). Susceptible Balb/c mice had a delayed
cytokine response, which was Th-2 skewed including IL-5 and IL-
4 production, and was associated with delayed parasite-specific
responses and exacerbated hypergammaglobulinemia (Fig. 9). The
apparent delay in cytokine responses and the lack of detectable IL-
4 until day 28 post-infection in susceptible Balb/c mice may have
been due to rapid consumption of these cytokines, especially IL-4,
rather then lack of their production. Overall, these data suggest
that the early Th-1 cytokine burst in susceptible mice may have
dampened parasite-mediated polyclonal B cell activation, allowing
for improved parasite-specific humoral responses, whereas sus-
tained Th-2 cytokine production in susceptible mice may
exacerbate parasite-induced polyclonal B cell activation. As B
cells have been shown to produce cytokines in response to parasite-
derived mitogenic factors [85], it is possible that B cell activation
Figure 9. Differential antibody and cytokine responses associated with resistance to T. cruzi. These plots model responses in T. cruzi
infected C57Bl/6 and Balb/c mice compared to control mice inoculated with heat-inactivated parasite (original data in Fig 1–5) and show the
association of parasite-specific antibody responses in the blood and spleen with decreased polyclonal antibody responses and differential cytokine
expression (kinetics and quality summarized here). Serum cytokine levels (see Fig 3 for details) in C57Bl/6 compared to controls were IFN-c.TNF-
a= IL-6.IL-10 with significantly elevated IL-12p40 and undetectable IL-5. The overall cytokine profile of Balb/c mice was IL-10$IL-5, IL-6, and TNF-a,
with increased IFN-c and IL-12p40 later during infection (Fig. 3). The isotype of serum IgGs for C57Bl/6 mice were IgG1.IgG3.IgG2b.IgG2c,
whereas Balb/c mice were IgG1.IgG2a.IgG3.IgG2b (Fig 4). Weight; the y-intercept is 100% and the origin is approximately 80% of the baseline.
Parasitemia; the origin is the limit of detection (104 parasites/mL) and peak parasitemia approximately 56105 parasites/mL. For cytokine responses,
serum IgG, and parasite-specific IgM/G in both the blood and the spleen, the y-axis is the relative change in infected versus control mice and is to
scale for each measure (i.e. directly compare IgG between C57Bl/6 and Balb/c mice). The plots for serum IgG are offset above the others for clarity.
doi:10.1371/journal.pntd.0000733.g009
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may account for some of the observed increases in cytokine levels
post-infection with T. cruzi.
Cytokines can drive antibody production and influence isotype
switch [86].The differential production of cytokines in susceptible
Balb/c versus resistant C57Bl/6 mice was associated with
differential total and parasite-specific IgG isotype response over
the course of acute infection (Fig 2, 3, and 9). IgG1 and IgG2a
made up the majority of the hypergammaglobunemia in Balb/c
mice, whereas C57Bl/6 mice had a much lower IgG1 and IgG2a
responses and increased total IgG2b (Fig 4). While IgG1 was the
most elevated isotype in both mouse models, IgG2a showed a
much greater increase from baseline in Balb/c and IgG2b in
C57Bl/6 mice. C57Bl/6 mice experienced isotype switching of
parasite-specific antibodies to IgG1, IgG2c, IgGb, and IgG3. In
contrast, the Balb/c mice had limited isotype switching; the
parasite-specific response remained predominately IgG1 and
IgG2a out to day 28 post-infection. These data confirm the
previously reported trend towards differential IgG isotype
responses in resistant versus susceptible mice [19,20] and further
support the association of parasite-specific IgG2, particularly
IgG2b, with increased resistance to T. cruzi [10,87,88].
Previous studies have reported B cell expansion in the spleen
during T. cruzi infection [12,20,21,28,31,89]. This expansion is
increased when intact CD4 T-cell responses are present [21] and
evidence shows that it is dissociated from parasite specific
responses [12], although some studies report both total and
specific B cell responses. In the present study, we performed a
detailed analysis of the B cell response to infection and found that
although total numbers of B cells were expanded to similar extents
in susceptible and resistant mice, the outcome of these expansions
were different in terms of production of total and specific IgG
ASC, activation status by CD69, CD86, Fas/FasL expression, and
B cell subset expansion (Fig 5–7).
Splenic B cell expansion in susceptible Balb/c mice was
associated with increased numbers of B cell blasts, as well as
with increased numbers of IgG ASC, without appreciable
expansion of parasite specific IgG ASC. In contrast, B cell
expansion in resistant C57Bl/6 mice led to moderately
increased B cell blast formation, moderate to low levels of IgG
ASC, and the formation of parasite-specific IgG ASC (Fig 5).
CD69, a marker of lymphocyte activation [88], was moderately
increased on Balb/c splenocytes throughout infection, whereas
in C57Bl/6 mice, CD69 was differentially expressed over the
course of acute infection, with an early peak expression that was
two fold higher on C57Bl/6 B cells compared to Balb/c B cells.
The early rise in CD69 on C57Bl/6 B cells preceded parasite-
specific ASC formation, after which CD69 levels decreased
(Fig. 6). These data demonstrated that transient high level CD69
expression preceded parasite-specific B cell activation, while
moderate sustained CD69 expression was associated with
polyclonal B cell activation. Previous studies have indicated a
role for increased CD86 on B cells during T. cruzi infection in
leading to increased immunoglobulin production through
interaction with NK cells [90]. In this study, CD86 expression
on B cell was not significantly different between these two
models early in infection, but diverged later with increased
levels of Balb/c B cells at day 28 post-infection concomitant
with peak hypergammaglobulinemia in these mice.
Recent studies have indicated that T. cruzi causes parasite
specific B cells to undergo Fas-FasL mediated fratricide [30].
Fas is also expressed on B cells during germinal center reactions,
without leading to apoptosis (reviewed in [91]). Our data shows
that Fas and FasL were differentially expressed on the surface of
B cells in C57Bl/6 versus Balb/c mice during T. cruzi infection
(Fig 6). In resistant C57Bl/6 mice, increased Fas and FasL
positive B cell numbers were associated with CRP-specific IgG
ASC. Fas and FasL were also increased on T cells in
conjunction with this CRP-specific IgG response in the spleen.
Together, these data suggest that the Fas/FasL expression on B
cells in C57Bl/6 mice was associated with a productive,
germinal-center like, reaction in the spleen. In contrast, elevated
Fas/FasL positive B cell numbers in susceptible Balb/c mice
were not associated with a parasite-specific response. Rather,
the sustained elevated expression of these death ligands may
have limited the non-specific expansion of B cells in these mice
through B-cell fratricide, as increased activation and blast
formation did not lead to overwhelming expansion of B cells
during acute infection.
To better understand which B cells account for the observed
increase in splenic B cells during T. cruzi infection, we evaluated B
cell subsets based on CD21 and CD23 expression of CD19+ B
cells (Fig 7). These markers have previously been used to define
splenic B cell subsets ex vivo during microbial infection
[36,37,67,68,69]. As the expression of these markers may be
modulated by activation induced by infection, the definition of
these subsets is not definitive. Future studies are necessary to define
the affect of T. cruzi infection on these B cell subsets in vivo. For
the purposes of this study, B cell subset populations were defined as
CD19+CD21highCD23low/2 (MZ B cells), CD19+CD21intCD23+
(FO B cells) and CD19+CD21lowCD23low/2 cells. In Balb/c mice,
B cells retained CD21 expression, but decreased CD23 expression,
the low affinity IgE receptor. Susceptible mice had an apparent
increase in B cells with the MZ phenotype within total B cells and
B cell blasts that was associated with polyclonal rather than
parasite-specific humoral responses (Fig. 5). Two possible
explanations for the expansion of B cells with the MZ phenotype
are that MZ B cells proliferated or parasite activation induced B
cells differentiation toward a MZ B cell phenotype. MZ B cells
were not expanded early in infection in C57Bl/6 mice. Rather,
transient expansion in MZ phenotype within B cells and B cells
blasts coincided with the development of parasite-specific IgG
ASC in resistant C57Bl/6 mice. The percentages of B cells with a
FO phenotype decreased in both models, but were retained to a
greater extend in the C57Bl/6 mice, although the variability
between mice was quite high, leading to a lack of significant
difference in absolute numbers of FO in C57Bl/6 versus Balb/c
mice. The relative amount of B cells with the FO phenotype within
the B cell blast population was higher during early infection of
C57Bl/6 mice compared to Balb/c mice, suggesting that in the
context of parasite-specific response B cell blasts retain the FO
phenotype to a greater extend than in the context of polyclonal B
cell activation. Analysis of CD19+CD21lowCD23low/2 cells
indicated that Balb/c mice experienced increased expansion of
these cells compared to C57Bl/6 mice. The expansion of
transitional B cells without parasite-specific ASC in susceptible
mice suggests that this expansion results from polyclonal B cell
activation rather than parasite-specific humoral immunity. The
relatively low representation of this population in the total number
of B cell blasts in susceptible mice suggests that perhaps decreased
CD23 expression, rather than proliferation led to the relative
expansion of this subset compared to controls. All together, these
data indicate differential changes in B cell subset phenotype in
resistant versus susceptible mice. Further studies are needed to
fully define the functional consequence of these apparent B cell
subset changes and their contribution to humoral response during
T. cruzi infection.
To evaluate whether these differences in humoral response were
associated with differences in T cell dynamics in resistant versus
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susceptible mice, bulk splenic T cells were analyzed for expansion,
blast formation, and expression of Fas and FasL (Fig 8). T cell
expansion was coincident with the generation of parasite specific
IgG responses at day fifteen post-infection in resistant mice, but
remained near control levels in during the polyclonal B cell
activation in susceptible mice at this same time-point. CD69
expression on total T cells was similar early during infection for
both models. Later in infection, T cells from infected Balb/c mice
experienced a second wave of CD69 activation, which was
coincident with clearance of parasite from circulation and the first
detection of parasite-specific IgG in circulation, although these
levels did increase much until later on during infection (after day
36). Low Fas and FasL expression in Balb/c mice suggests that the
contribution of T cells to control of B cell numbers via apoptosis
was minimal in these mice. The expression of Fas and FasL on T
cells coincided with parasite-specific B cell responses in C57Bl/6
mice, suggesting they may have formed a productive association.
Further analysis of T cells at this time-point indicated that resistant
mice had significantly higher levels of CD4 and NK T cells than
susceptible mice, both of which can provide B cell help [92]. While
previous studies show that lack of CD4 T cells led to decreased
polyclonal B cell activation [21], these results suggest that
maintenance of CD4 and increased NK T cells may also be
important for directing the efficacy of the specific humoral
response to parasite antigen. Activation of NK T cells has
previously been linked to increased resistance to T. cruzi, but
depends upon the presence of CD8 and CD4 T cells, as well as
IFN-c production [93,94]. The increased numbers of NK T cells
in resistant C57Bl/6 mice is particularly intriguing as they may
provide B cell help through direct interaction (CD40L) or rapid
cytokine responses, especially IFN-c, which was produced to a
much greater extent in these resistant mice [95]. These data
provide rationale for further studies to fully define the contribution
of CD4 and NK T cells to polyclonal versus parasite-specific
humoral immunity during T. cruzi infection of susceptible versus
resistant mice.
While susceptibility and resistance of Balb/c and C57Bl/6 mice
have been documented and explored in terms of cellular and
cytokine responses to T. cruzi experimental infection
[2,49,78,79,96,97,98,99,100,101], humoral responses in these
studies have been largely neglected. This is the first study to
examine both polyclonal and specific humoral responses in these
mice in the context of equivalent initial parasitemia. Taken
together, the results in this study support the hypothesis that
polyclonal B cell activation leading to hyper-IgG responses are
associated with increased disease susceptibility and highlights the
importance of host-parasite interactions in development of
humoral responses to T. cruzi. By further characterizing associa-
tions between Th1 and Th2 responses, the development of
polyclonal versus parasite-specific humoral responses, and the
potential contribution of B cell subsets to these processes, this
present study provides a more detailed understanding of the
development of effective versus detrimental humoral responses
during T. cruzi infection. Furthermore, these results have
implications for vaccine design in T. cruzi, as host genetic biases
that lead to differential polyclonal B cell activation may have
profound effects on the development of humoral immunity to T.
cruzi target antigens [14,102,103].
Supporting Information
Figure S1 Survival curves and parasitemia profile of mice
infected with Y strain variants. Mice (5–10 per dose) were injected
i.p. with TCT derived parasites and monitored for survival and for
parasite numbers in tail blood. A, Top: Babl/c mice inoculated
with the indicated doses of Y-Br variant. Middle: C57Bl/6 mice
inoculated the indicated doses of Y-Br variant. Bottom: Balb/c
mice inoculated with the indicated doses of Y-US variant. B,
Parasitemia profiles for Balb/c mice inoculated with 10 (,LD50)
or 50 (2–36LD50) Y-Br variant parasites, or C57Bl/6 mice with
10,000 Y-Br parasites (,0.5LD50).
Found at: doi:10.1371/journal.pntd.0000733.s001 (0.24 MB
DOC)
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